|本期目录/Table of Contents|

[1]王小东,庄少伟,张旭敏,等.替格瑞洛对老年急性心肌梗死患者血小板功能及临床预后的影响[J].国际心血管病杂志,2016,03:183-186.
　WANG Xiaodong,ZHUANG Shaowei,ZHANG Xumin,et al.Effect of ticagrelor on platelet reactivity and clinical outcome in elderly acute myocardial infarction patients[J].International Journal of Cardiovascular Disease,2016,03:183-186.
点击复制

替格瑞洛对老年急性心肌梗死患者血小板功能及临床预后的影响(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2016年03期
页码:
183-186
栏目:
临床研究
出版日期:
2016-05-20

文章信息/Info

Title:
Effect of ticagrelor on platelet reactivity and clinical outcome in elderly acute myocardial infarction patients
作者:
王小东; 庄少伟; 张旭敏; 周华; 来晏; 康晟; 夏光; 周建; 刘学波
200120 上海,同济大学附属东方医院心内科
Author(s):
WANG Xiaodong;  ZHUANG Shaowei;  ZHANG Xumin;  ZHOU Hua;  LAI Yan;  KANG Sheng;  XIA Guang;  ZHOU Jian;  LIU Xuebo.
Department of Cardiology,Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China
关键词:
替格瑞洛; 氯吡格雷; 老年
Keywords:
Ticagrelor;  Clopidogrel;  Elderly
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2016.03.015
文献标识码:
-
摘要:
目的:探索替格瑞洛联合阿司匹林对老年急性心肌梗死(AMI)患者血小板功能及临床预后的影响。方法:纳入2013年10月至2014年10月期间在我院就诊的老年(≥65岁)AMI患者200例,随机分为氯吡格雷组(n=101)和替格瑞洛组(n=99),分别给予负荷量阿司匹林300mg+氯吡格雷600mg或阿司匹林300mg+替格瑞洛180mg,次日起改为维持剂量阿司匹林100mg/d和氯吡格雷75mg/d或替格瑞洛180mg/d,用药前及用药后1、6和12个月分别检测血小板反应指数(P
Abstract:
Objective: To evaluate the effect of ticagrelor with aspirin on platelet activity and clinical outcome in elderly patients with of acute myocardial infarction(AMI).Methods:A number of 200 elderly AMI patients from October 2013 to October 2014 were involve

参考文献/References

[1] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel versus clopidogrel coronary syndrome[J]. N Engl J Med, 2009, 361(11): 1045-1057.
[2] Thygesen K, Alpert JS, White HD, et al. Joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction[J]. Eur Heart J, 2007, 28(20): 2525-2538.
[3] Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents[J]. N Engl J Med, 2007, 356(10): 1020-1029.
[4] Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction(TIMI)Trial--phase Ⅰ: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator andstreptokinase[J]. J Am Coll Cardiol, 1988, 11(1): 1-11.
[5] O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2013, 61(4): e78-e140.
[6] Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST- Segment Elevation of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2016, 37(3): 267-315.
[7] 沈卫峰,张 奇,张瑞岩. 2015年急性ST段抬高型心肌梗死诊断和治疗指南解析[J]. 国际心血管病杂志,2015,42(4):217-219.
[8] 骆景光,韩 凌,杨 明,等. 替格瑞洛对高血小板反应性高危非ST段抬高型急性冠脉综合征患者血小板聚集率的影响[J]. 国际心血管病杂志,2015,42(2):133-134.

备注/Memo

备注/Memo:
基金项目:上海市浦东新区卫生与计划生育委员会面上项目(PW2014A-16) 作者单位:200120 上海,同济大学附属东方医院心内科 通信作者:刘学波,Email:lxb70@hotmail.com
更新日期/Last Update: 2016-05-20